News & Updates

Original New Drug Application Approvals by US FDA (16-31 March 2025)

New drug applications approved by US FDA as of 16-31 March 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

What’s new in advanced urothelial carcinoma?

Enfortumab vedotin and pembrolizumab’s (EV+P) EV-302 trial results represent a major advancement in metastatic urothelial carcinoma (mUC), including in Asian patients, according to Professor Ravindran Kanesvaran of the National Cancer Centre in Singapore, who also discussed managing skin toxicity associated with this regimen and provided an overview of other agents for UC under investigation at Uro-Oncology Asia 2025.

Pembrolizumab plus lenvatinib: A standard of care in first-line treatment of advanced RCC

Therapeutic advancements based on immuno-oncology (IO) combinations have revolutionized the treatment landscape for renal cell carcinoma (RCC). In particular, front-line use of immune checkpoint inhibitors combined with tyrosine kinase inhibitors (TKIs) offers superior survival benefits compared with TKI monotherapy or IO-IO combinations. At the 10^th Annual Scientific Meeting of the Hong Kong Society of Uro-Oncology (HKSUO) (Uro- Oncology Asia 2025), Professor Viktor Grünwald of the University Hospital Essen, Essen, Germany, presented recent data supporting the broad antitumour activity of pembrolizumab plus lenvatinib in patients with clear- and non-clear-cell RCC histologies.

Microultrasonography a promising alternative to MRI for image-guided prostate biopsy

Microultrasonography-guided biopsy performs similarly as MRI/conventional ultrasonography fusion-guided biopsy in terms of detecting Gleason Grade Group 2 or higher prostate cancer in biopsy-naïve men, according to the results of the multicentre, international OPTIMUM study.

Skin fairness creams not fair to the kidneys

A recent review integrates multiple research findings and turns the spotlight on the growing nephrotoxic threat posed by skin-whitening creams.

How to optimize treatment strategies for mHSPC by integrating pivotal data?

Theranostics in prostate cancer management: Current strategies and real-world data

Earlier use of lutetium-177 (¹⁷⁷Lu) prostate-specific membrane antigen (PSMA)–radioligand therapy (RLT) in combination with chemotherapy is shaping the future of prostate cancer management, according to Dr Yu-Yi Huang of the Department of Nuclear Medicine, Koo-Foundation Sun Yat-Sen Cancer Center (SYSCC), Taiwan, at Uro-Oncology Asia 2025.